MedicalMinute: Next Steps Following TNF Inhibitor Failure in IBD

Learn about current guideline recommendations for therapeutic drug monitoring of TNF-α inhibitor therapy and review key data informing second-line treatment decisions of moderate to severe UC and CD following TNF-α inhibitor failure.
Bruce E. Sands, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 337 KB
Released: May 24, 2021

Acknowledgements

Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Bristol-Myers Squibb

Related Content

Expert commentary from Dr. Millie Long on developing “activated” patients with IBD in your practice, from Clinical Care Options (CCO)

Millie D. Long, MD, MPH Released: July 13, 2021

Downloadable slides covering best practices of shared-decision making and discussing cancer risk when discussing initiation of biologic therapy with patients who have IBD

Millie D. Long, MD, MPH Released: June 24, 2021

Expert commentary from Dr. Bruce Sands on therapeutic drug monitoring in IBD, from Clinical Care Options (CCO)

Bruce E. Sands, MD, MS Released: June 3, 2021

Interactive video from Dr. Bruce Sands and Clinical Care Options (CCO): IBD management after TNF inhibitor failure

Bruce E. Sands, MD, MS Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: May 24, 2021 Expired: May 23, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue